Skip to main content
Premium Trial:

Request an Annual Quote

Horizon, UK NEQAS Team on Standards for Lung Cancer Biomarkers

NEW YORK (GenomeWeb News) – Horizon Diagnostics, a division of Cambridge, UK-based Horizon Discovery, said today that it will collaborate with the UK National External Quality Assessment Service on genetically defined reference standards for novel lung cancer biomarkers.

Horizon said that it has developed human genomic reference standards containing defined allelic ratios, which offer "an unprecedented level of control to the diagnostics industry" and will be used to minimize variability in FISH and immunohistochemistry-based testing.

UK NEQAS will receive an exclusive license to distribute the reference standards related to certain lung cancer biomarkers in the UK and Europe for the purpose of proficiency testing within its quality assessment program.

"Horizon's application of its gene editing technology in development of reference standards is ideally suited to diagnostics proficiency testing," Keith Miller, director of UK NEQAS, said in a statement. "We look forward to working with them as the field of cancer therapeutics moves increasingly toward a more personalized approach."

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.